AR026066A1 - VIRAL PARTICLES WITH EXOGENOUS INTERNAL EPITHOPES. - Google Patents

VIRAL PARTICLES WITH EXOGENOUS INTERNAL EPITHOPES.

Info

Publication number
AR026066A1
AR026066A1 ARP000105455A ARP000105455A AR026066A1 AR 026066 A1 AR026066 A1 AR 026066A1 AR P000105455 A ARP000105455 A AR P000105455A AR P000105455 A ARP000105455 A AR P000105455A AR 026066 A1 AR026066 A1 AR 026066A1
Authority
AR
Argentina
Prior art keywords
expression
viruses
viral particles
epithopes
peptides
Prior art date
Application number
ARP000105455A
Other languages
Spanish (es)
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of AR026066A1 publication Critical patent/AR026066A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8202—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector
    • C12N15/8203—Virus mediated transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se relaciona con la expresion de péptidos en partículas virales, y más particularmente con la expresion de péptidos en el interior del cápsido viral. Sedescriben métodos para modificar los virus, de tal manera de tal manera que los epítopos exogenosse expresen en el interior del cápsido viral. Los virus quese pueden modificar incluyen virus de ARN de cadena (+), especialmente virus de ARN de cadena (+) de planta, tales como el virus de mosaico de caupí. Laexpresion interna es especialmente utilpara la expresion de epítopos hidrofobicos. Las partículas virales modificadas también encuentran uso como vacunas, ycomo tales son capaces de producir una respuesta inmune.It is related to the expression of peptides in viral particles, and more particularly to the expression of peptides inside the viral capsid. Methods for modifying viruses are described, such that the exogenous epitopes are expressed inside the viral capsid. Viruses that can be modified include chain RNA (+) viruses, especially plant chain (+) RNA viruses, such as cowpea mosaic virus. Internal expression is especially useful for the expression of hydrophobic epitopes. Modified viral particles also find use as vaccines, and as such they are capable of producing an immune response.

ARP000105455A 1999-10-14 2000-10-17 VIRAL PARTICLES WITH EXOGENOUS INTERNAL EPITHOPES. AR026066A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924352.9A GB9924352D0 (en) 1999-10-14 1999-10-14 Methods,compositions and applications relating to the generation of novel plant viral particles

Publications (1)

Publication Number Publication Date
AR026066A1 true AR026066A1 (en) 2002-12-26

Family

ID=10862753

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105455A AR026066A1 (en) 1999-10-14 2000-10-17 VIRAL PARTICLES WITH EXOGENOUS INTERNAL EPITHOPES.

Country Status (16)

Country Link
EP (1) EP1235910A1 (en)
JP (1) JP2003534771A (en)
KR (1) KR100880477B1 (en)
CN (2) CN101591647A (en)
AR (1) AR026066A1 (en)
AU (1) AU785020B2 (en)
BR (1) BR0014861A (en)
CA (1) CA2387626A1 (en)
CO (1) CO5280142A1 (en)
CZ (1) CZ20021303A3 (en)
GB (1) GB9924352D0 (en)
IL (1) IL149077A0 (en)
MX (1) MXPA02003789A (en)
PL (1) PL354933A1 (en)
WO (1) WO2001027282A1 (en)
ZA (1) ZA200202815B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454882A1 (en) * 2001-06-21 2003-01-03 Uab Research Foundation Chimeric capsid proteins and uses thereof
EP2272525A3 (en) 2002-07-05 2011-11-16 Folia Biotech Inc. Adjuvant viral particle
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
CA2583113C (en) 2004-10-05 2015-11-10 Diversa Corporation Compositions comprising an antigen and a promiscuous t-cell epitope
AU2006309286A1 (en) * 2005-06-01 2007-05-10 Dow Global Technologies, Inc. Production of multivalent virus like particles
KR20080028941A (en) * 2005-07-19 2008-04-02 다우 글로벌 테크놀로지스 인크. Recombinant flu vaccines
WO2009014782A2 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2013003353A2 (en) * 2011-06-30 2013-01-03 Stc.Unm Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108386D0 (en) * 1991-04-19 1991-06-05 Agricultural Genetics Co Modified plant viruses as vectors
GB9712282D0 (en) * 1997-06-12 1997-08-13 Innes John Centre Innov Ltd Epitope presentation system

Also Published As

Publication number Publication date
EP1235910A1 (en) 2002-09-04
GB9924352D0 (en) 1999-12-15
KR100880477B1 (en) 2009-01-28
BR0014861A (en) 2002-07-16
CN1471580A (en) 2004-01-28
MXPA02003789A (en) 2002-09-30
WO2001027282A1 (en) 2001-04-19
CO5280142A1 (en) 2003-05-30
CA2387626A1 (en) 2001-04-19
AU785020B2 (en) 2006-08-24
IL149077A0 (en) 2002-11-10
CZ20021303A3 (en) 2002-10-16
PL354933A1 (en) 2004-03-22
KR20020040868A (en) 2002-05-30
WO2001027282A8 (en) 2001-08-16
JP2003534771A (en) 2003-11-25
CN101591647A (en) 2009-12-02
ZA200202815B (en) 2003-08-27
AU1085201A (en) 2001-04-23

Similar Documents

Publication Publication Date Title
EA200801756A1 (en) ANTIGRIPOPOSIC VACCINES CONTAINING HEMAGGLUTININ AND PROTEINS OF MATRIX
EA200900784A1 (en) VACCINES INCLUDING ANTIGENS FROM FOUR STRAINS OF THE INFLUENZA VIRUS
CO2018005265A2 (en) Nucleic acid vaccines for varicella-zoster virus
PE20110020A1 (en) IMMUNOMODULATION THROUGH THE USE OF PLACENTA STEM CELLS
PE20220379A1 (en) DELIVERY OF BIOMOLECULES TO PBMC TO MODIFY AN IMMUNE RESPONSE
PT1294893E (en) MODIFICATION OF HEPATITIS B NUCLEAR ANTIGEN
AR026066A1 (en) VIRAL PARTICLES WITH EXOGENOUS INTERNAL EPITHOPES.
UY30485A1 (en) ANTIVIRAL USE OF A CATIONIC TENSIOACTIVE
ES2263406T1 (en) PRODUCTION OF CAPSIDA L1 PROTEIN AND HUMAN PAPILOMAVIRUS VIRUS TYPE VIRUS PARTICLES HBV-11.
EA201270191A1 (en) LENTIVIRAL VECTORS PSEUDOTYPED BY GLYPROTEIN SHELL OF THE SYNBIS VIRUS
AR033574A1 (en) A BACTERIAL CEPA OF THE LACTIC BACTERIA GROUP CAPABLE OF REDUCING THE TREND OF AN INDIVIDUAL TO DEVELOP ALLERGIC REACTIONS, FOOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND THE VACCINES CONTAINING IT
AR049176A1 (en) VACCINE UNDERSTANDING A DENIED PESTIVIRUS
AR058049A1 (en) VIRUS CAPSIDA PROTEIN DENG INDUCTING PROTECTIVE RESPONSE AND PHARMACEUTICAL COMPOSITION
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
AR115069A1 (en) SYNTHETIC CHEMERIC VACCINE VIRUS
PA8813901A1 (en) DAMAGED ONCOLITICAL PARAMIXOVIRUS THAT CODIFY BIRD CYTOKINS
MX2013013228A (en) Virus-like particles and process for preparing same.
WO2007046839A3 (en) New live virus vaccines
AR004464A1 (en) A METHOD FOR PRODUCING A PAPILOMAVIRUS CAPSIDE PROTEIN
WO2011150320A3 (en) Activators of innate immunity
IL265524B2 (en) Assembled glycoproteins
EP1420819A4 (en) Sub-unit vaccine for infectious pancreatic necrosis virus
BRPI0411099A (en) immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus proteins antigens
WO2002038793A3 (en) Hepatitis c virus constructs characterized by high efficiency replication
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus

Legal Events

Date Code Title Description
FB Suspension of granting procedure